308 results on '"Shirota, Hidekazu"'
Search Results
2. Pretreatment neutrophil–lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab
3. Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial
4. Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial
5. Management of patients with presumed germline pathogenic variant from tumor-only genomic sequencing: A retrospective analysis at a single facility
6. TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer
7. Specific cancer types and prognosis in patients with variations in the KEAP1‐NRF2 system: A retrospective cohort study.
8. Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers
9. Chylous Ascites Associated with Advanced Pancreatic Cancer That Improved with Appropriate Treatment: A Case Report
10. Patient survey on cancer genomic medicine in Japan under the national health insurance system
11. Correlation between Efficacy and Cardiovascular Adverse Events in Patients with Advanced Solid Cancer Who Received VEGF Pathway Inhibitors: Hypertension within the First Eight Weeks is Associated with Favorable Outcomes of Patients Treated with VEGF Pathway Inhibitors
12. Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei
13. Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study.
14. MO10-2 Clinical decisions by the Molecular Tumor Board on comprehensive genomic profiling tests in Japan: A retrospective observational study
15. P8-5 Calculation of medical personnel expenses to conduct a comprehensive genomic profiling test in Japan
16. Comparison of efficacy and safety between carboplatin-etoposide and cisplatin-etoposide combination therapy in patients with advanced neuroendocrine carcinoma, retrospective study
17. Contribution of Fcγ receptor IIB to creating a suppressive tumor microenvironment in a mouse model
18. Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma
19. Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma.
20. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial)
21. Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors
22. Distinct role of CD8 cells and CD4 cells in antitumor immunity triggered by cell apoptosis using a Herpes simplex virus thymidine kinase/ganciclovir system
23. Human resources for administrative work to carry out a comprehensive genomic profiling test in Japan
24. Abstract 6389: Differential role of CD8 cells and CD4 cells in anti-tumor immunity triggered by tumor cell apoptosis using HSVtk/GCV system
25. Abstract 3225: Real-world surveillance from cancer patients about their experience of comprehensive genomic profiling tests in Japan
26. Data from IL4 from T Follicular Helper Cells Downregulates Antitumor Immunity
27. Supplementary Figure 2 from IL4 from T Follicular Helper Cells Downregulates Antitumor Immunity
28. Supplementary Figure 1 from IL4 from T Follicular Helper Cells Downregulates Antitumor Immunity
29. Supplementary Figure 3 from IL4 from T Follicular Helper Cells Downregulates Antitumor Immunity
30. Supplementary Figure Legend from IL4 from T Follicular Helper Cells Downregulates Antitumor Immunity
31. TP53 gain of function mutation as a prognostic factor in high-methylated metastatic colorectal cancer: Translational research of TRICOLORE study.
32. IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model
33. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan
34. Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study
35. Vaccine Adjuvants
36. Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugs
37. BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
38. Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors.
39. A novel role for IL-22R1 as a driver of inflammation
40. Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial
41. Antibiotic Treatment Improves the Efficacy of Oxaliplatin-Based Therapy as First-Line Chemotherapy for Patients with Advanced Gastric Cancer: A Retrospective Study
42. Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study.
43. Short- and long-term changes in gene expression mediated by the activation of TLR9
44. Contribution of IRF-3 mediated IFNβ production to DNA vaccine dependent cellular immune responses
45. TLR-9 Agonist Immunostimulatory Sequence Adjuvants Linked to Cancer Antigens
46. CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity
47. Recent progress concerning CpG DNA and its use as a vaccine adjuvant
48. Wide-Targeted Metabolome Analysis Identifies Potential Biomarkers for Prognosis Prediction of Epithelial Ovarian Cancer
49. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring HER2 amplification (JUPITER trial).
50. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.